Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 Beyond Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
SEATTLE, WA — (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that… Read More




